Among the 13 patients enrolled in the UBC cohort, the tumors from eight exhibited heterogeneous HER2 protein expression (30%–70% of tumor cells) by IHC; the other five exhibited homogeneous HER2 staining (>70% of tumor cells). This evidence concerns the gene ERBB2 and neoplasm.